Lansopon 15 mg, 30 mg udviser et gunstigt benefit/ risk- forhold, forudsat at der indføjes passende oplysninger vedrørende eradikationsbehandlingen for H. pylori i produktresuméet.
The risk/ benefit ratio of Lansopon 15 mg, 30 mg is considered to be favourable provided that appropriate information regarding H. pylori eradication therapy are included in the SPC.